Overview

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

Status:
Recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)

Phase:

Phase 3

Details

Lead Sponsor:

Kodiak Sciences Inc

Treatments:

Aflibercept